Navigation Links
Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
Date:5/17/2013

worldwide.  Many people with epilepsy take multiple medications, yet the published literature suggests that as many as one-third are unable to control their seizures with current therapies.  INS001 has a unique mechanism of action that suggests it could potentially provide superior efficacy either as a stand-alone therapy or when given in combination with other epilepsy drugs.

The Antiepileptic Drug and Device Trials (AED) XII Conference is sponsored by the Epilepsy Study Consortium in collaboration with the University of Pennsylvania Epilepsy Center and the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation.  For more information, visit www.epilepsy.com/etp/aedtrialxii.

About Insero Health
Insero Health is a clinical-stage company that discovers and develops small molecule therapies derived from natural products to address significant unmet needs in neurological diseases.  The company's initial target is epilepsy, a debilitating disorder that affects approximately 3 million people in the U.S. and over 50 million people worldwide.  The company is based in Miami, Florida, at the University of Miami Life Science and Technology Park.  For more information, visit www.inserohealth.com.

Contact:
BLL Partners, LLC
Barbara Lindheim
212 584-2276
blindheim@bllbiopartners.com 

 


'/>"/>
SOURCE Insero Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013
2. Best Practices for Tracking Tissue in the Healthcare Supply Chain, Webinar Hosted by Xtalks
3. Cambrex To Present At UBS Global Healthcare Conference
4. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. ViroPharma To Participate In Two May Healthcare Investor Conferences
7. PrimeraDx Featured in the Goldman Sachs Healthcare Research Teams GS Emerging Healthcare Series
8. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
9. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
10. CellHealth Institute is Named 2013 Edison Award Winner
11. AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... its investment in the development and manufacture of highly valued cardiac markers used ... scientific team's extensive expertise with protein chemistry has led to the development and ...
(Date:8/26/2015)... SAN FRANCISCO , Aug. 26, 2015 /PRNewswire/ ... today that it has received a $1.5M Phase ... Health (NIH) to further develop its therapeutic agent ... unmet clinical need in end stage renal disease ... by the National Institute of Diabetes and Digestive ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... 17 , - MedITEX IVF Facilitates ... - MedITEX from 28 June to 1 ... The IT consulting company CRITEX, which specialises in ... fertilisation, MedITEX IVF,at the 25th Annual Meeting of the European Society ...
... , FREMONT, Calif., June 16 Microfluidic Systems, ... patent number 7,541,166, entitled "Sonication to Selectively Lyse ... the process of differential extraction of male/female DNA ... in a wide variety of biological sample processes ...
... and Webcast on Wednesday, June 17 at 8:30 a.m. Eastern ... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... Food and Drug Administration (FDA) recommended by a vote of ... PEGylated uricase enzyme, be granted marketing approval by the FDA ...
Cached Biology Technology:New IVF Software MedITEX to be Presented at the ESHRE Exhibition 2MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis. 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 3FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 4
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... rises -- plants, ozone absorption is curtailed, leaving more pollution ... the UK in the hot summer of 2006. , Vegetation ... research by the Stockholm Environment Institute (SEI) at the University ... we need it most: during extreme heat, when ozone formation ...
... Case Western Reserve University School of Medicine have identified ... from changing its molecular shape into the abnormal form ... July 18 issue of Cell Reports , offers ... until now has always proved fatal. Prion diseases ...
... is now open for the Mushrooms and Health Summit held ... 9-10, 2013. The meeting is of interest to scientists, writers ... comprehensive examination of the global research that links mushrooms to ... scientific event , Learn from the world,s top scientists, ...
Cached Biology News:It's not just the heat -- it's the ozone: Study highlights hidden dangers 2It's not just the heat -- it's the ozone: Study highlights hidden dangers 3New approach to protecting prion protein from altering shape 2
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
... Series of positioning slides offers multiple ... leadscrew, micrometer, and manual. With this ... cost-effective multi-axis systems. These slides also ... resolutions down to 10 nanometers, integrated ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: